Canada - English - Health Canada

sandoz canada incorporated - docetaxel - solution - 10mg - docetaxel 10mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

northstar rxllc - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel anhydrous 20 mg in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - docetaxel -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - docetaxel -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - docetaxel -

Ireland - English - HPRA (Health Products Regulatory Authority)

seacross pharmaceuticals limited - docetaxel anhydrous - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - docetaxel - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - docetaxel - concentrate for solution for infusion - 10 milligram(s)/millilitre - taxanes; docetaxel

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastic agents - treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - docetaxel 40 mg/ml;   - injection with diluent - 40 mg/ml - active: docetaxel 40 mg/ml   excipient: citric acid nitrogen polysorbate 80 ethanol nitrogen water for injection - head and neck cancer docetaxel, in combination with cisplatin and fluorouracil is indicated in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.